Drug Profile
Ezeprogind - AlzProtect
Alternative Names: AZP 2006Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator AlzProtect; INSERM; University of Lille 2
- Developer AlzProtect
- Class Antidementias; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Progranulin protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Progressive supranuclear palsy
- Phase I Alzheimer's disease
- Preclinical Parkinson's disease
Most Recent Events
- 13 Mar 2024 Alzprotect plans the pivotal phase-IIb/III PROMISE-PSP trial for Progressive supranuclear palsy in Europe and the US in late 2024
- 28 Aug 2023 3816685: Updated KDM, added AE/PK data and clinical HE; added OLE trial initiation HE; updated planned trial phase in FET
- 16 Jul 2023 Pharmacodynamics data from a preclinical studies in Progressive Supranuclear Palsy and Alzheimer’s Disease presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)